What is the price target for Omeros stock?
Their forecasts range from $5.00 to $100.00. On average, they expect Omeros' stock price to reach $31.40 in the next twelve months. This suggests a possible upside of 350.5% from the stock's current price. View analysts' price targets for Omeros or view top-rated stocks among Wall Street analysts. Who are Omeros' key executives?
Who sold Omer stock in the last quarter?
OMER stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Two Sigma Investments LP, Millennium Management LLC, Voloridge Investment Management LLC, Morgan Stanley, Citadel Advisors LLC, GSA Capital Partners LLP, and BlackRock Inc..
How do you buy shares of Omer?
Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What are analysts'price targets for Omeros'stock?
4 analysts have issued 12 month price objectives for Omeros' stock. Their forecasts range from $18.00 to $35.00. On average, they expect Omeros' stock price to reach $27.75 in the next year.
Is OMER a good stock to buy?
Out of 4 analysts, 0 (0%) are recommending OMER as a Strong Buy, 1 (25%) are recommending OMER as a Buy, 2 (50%) are recommending OMER as a Hold, 0 (0%) are recommending OMER as a Sell, and 1 (25%) are recommending OMER as a Strong Sell.
Why is OMER stock down?
Omeros stock is sinking today because the company told investors the FDA identified deficiencies that prevent the agency from taking the next step toward approving narsoplimab. This could be a minor case that isn't related to the drug candidate itself, but investors aren't taking any chances.
What is Narsoplimab?
Narsoplimab is a fully human monoclonal antibody that binds to and inhibits mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway and an activator of the coagulation cascade. In this pivotal clinical trial, narsoplimab safety and efficacy were evaluated in patients with HSCT-TMA.
Should I buy or sell Omeros stock right now?
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 sell rati...
What is Omeros' stock price forecast for 2022?
6 analysts have issued 1 year target prices for Omeros' stock. Their forecasts range from $4.00 to $100.00. On average, they expect Omeros' share p...
How has Omeros' stock price performed in 2022?
Omeros' stock was trading at $6.43 on January 1st, 2022. Since then, OMER stock has decreased by 67.5% and is now trading at $2.09. View the best...
When is Omeros' next earnings date?
Omeros is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Omeros .
How were Omeros' earnings last quarter?
Omeros Co. (NASDAQ:OMER) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.56) EPS for the quarter, top...
Who are Omeros' key executives?
Omeros' management team includes the following people: Dr. Gregory A. Demopulos M.D. , Co-Founder, Chairman, CEO & Pres (Age 63, Pay $2.24M) Mr....
What is Gregory A. Demopulos' approval rating as Omeros' CEO?
17 employees have rated Omeros CEO Gregory A. Demopulos on Glassdoor.com . Gregory A. Demopulos has an approval rating of 74% among Omeros' employ...
Who are some of Omeros' key competitors?
Some companies that are related to Omeros include Johnson & Johnson (JNJ) , Eli Lilly and (LLY) , Pfizer (PFE) , AbbVie (ABBV) , Merck & Co.,...
What other stocks do shareholders of Omeros own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD)...
Is Omeros stock a Buy, Sell or Hold?
Omeros stock has received a consensus rating of buy. The average rating score is and is based on 9 buy ratings, 3 hold ratings, and 0 sell ratings.
What was the 52-week low for Omeros stock?
The low in the last 52 weeks of Omeros stock was 2.04. According to the current price, Omeros is 100.25% away from the 52-week low.
What was the 52-week high for Omeros stock?
The high in the last 52 weeks of Omeros stock was 16.56. According to the current price, Omeros is 12.35% away from the 52-week high.
What are analysts forecasts for Omeros stock?
The 12 analysts offering price forecasts for Omeros have a median target of 28.08, with a high estimate of 100.00 and a low estimate of 4.00. The m...
What is Omeros Corp?
What is the P/E ratio of Omeros?
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Where is Omeros located?
The P/E ratio of Omeros is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Omeros pay dividends?
Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at (206) 676-5000 or via fax at 206-676-5005.
What is ZER research?
Omeros does not currently pay a dividend.
How many sectors are there in Zacks?
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Is ZacksTrade a separate company?
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
